A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Accupril
Synonyms :
quinapril
Class :
ACE inhibitors
Brand Name :
Accupril
Synonyms :
quinapril
Class :
ACE inhibitors
Dosage Forms & Strengths Â
Tablet Â
5mg Â
10mg Â
20mg Â
40mg Â
Dosage Forms & Strengths Â
Tablet Â
5mg Â
10mg Â
20mg Â
40mg Â
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with ACE inhibitors
may enhance the concentration of serum when combined with lithium
may increase the toxicity of each other by pharmacodynamic synergism
May diminish the effects of ketoprofen by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
grass pollens allergen extractÂ
may have an increasingly adverse effect when combined with grass pollen extract
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
choline magnesium trisalicylate
may enhance the nephrotoxic effect of ACE inhibitors
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
choline magnesium trisalicylate
salicylates may enhance the nephrotoxic effect of ACE Inhibitors
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased myelosuppressive effect when combined with azathioprine
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
spironolactone and hydrochlorothiazide
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
empagliflozin and linagliptinÂ
may increase the toxic effects of dipeptidyl peptidase-IV inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
sodium ferric gluconate complexÂ
concomitant administration of ACE inhibitors with sodium ferric gluconate complex should be used with caution as it may cause possible adverse reactions like hypersensitivity and low blood pressure
when co-administered with aminohippuric acid, the excretion of quinapril may be reduced
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
Adverse drug reactions Â
Frequency Defined Â
1-10% Â
Coughing (4.3%) Â
Rash (1.4%) Â
Headache (1.7%) Â
Dizziness (7.7%) Â
Diarrhea (1.7%) Â
Hypotension (2.9%) Â
Fatigue (2.6%) Â
Myalgia (1.5%) Â
Dyspnea (1.9%) Â
<1% Â
Back pain Â
Angioedema Â
Pregnancy warnings:   
Pregnancy: C for the first trimester; D for (2nd & 3rd trimester)Â
Lactation:Â Â
Excreted into human milk is knownÂ
Pregnancy Categories:       Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category Â
 Â
Patient Information Leaflet   Â
Generic Name: quinaprilÂ
Why do we use quinapril? Â
quinapril is an ACE inhibitor used to treat Hypertension, CHF, and Diabetic Nephropathy.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
